Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Parallel Import of Pharmaceutical Drugs to Russia (Q1 – Q2 2017)

Friday, August 4, 2017

Between January and June 2017, Russia imported 302,000 units of ready-made drugs worth 376.5 mln RUB (free circulation prices) without official permission of the rightholders. Over the year, the parallel import has risen by 49% in monetary terms and by 3 times in physical terms.

Over the period, imports of 21 trademarks could be deemed parallel, while in 2016 it was 10. Perfusion drug Custodiol (by Dr Franz Köhler Chemie) is the only one trademark has been subject to parallel import for the second consecutive year. In monetary terms, Jintropin (Somatropinum) by the British company Europharm is the leader in the parallel import, while the company is the leader in the total parallel import.

16 companies, usually small- and middle-sized ones with a short product line, participated in the parallel import. The top pharmaceutical companies in Russia have also been in, in particular Abbvie (Humira), Fresenius (Balance), Bayer (Alka-Seltzer.)

Between January and June 2017, the parallel imports included 10 countries, while in 2016 they were only 5. Georgia, Germany and Australia are the leaders, with more than 70% of the import. In monetary terms, the parallel import from Germany has risen by 89% since 2016.

Dynamics of parallel import of ready-made drugs to Russia, free circulation prices including customs clearance (2013 – 2016, Q1 – Q2 2017)

Share: